Literature DB >> 28286692

Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.

Junghwa Lee1, Eunseon Ahn1, Haydn T Kissick1, Rafi Ahmed1.   

Abstract

T-cell exhaustion due to persistent antigen stimulation is a key feature of chronic viral infections and cancer. Programmed cell death-1 (PD-1) is a major regulator of T-cell exhaustion, and blocking the PD-1 pathway restores T-cell function and improves pathogen control and tumor eradication. Immunotherapy targeting the PD-1 inhibitory receptor pathway has demonstrated significant antitumor activity. Recently, antibodies blocking PD-1 have been approved for use in cancer patients. In this review, we summarize the role of the PD-1 pathway in chronic infection and cancer and the therapeutic potential of PD-1-directed immunotherapy in patients with chronic infection or cancer.

Entities:  

Keywords:  T-cell exhaustion; cancer; chronic infection; immunotherapy; programmed cell death-1

Year:  2015        PMID: 28286692      PMCID: PMC5341794          DOI: 10.1615/ForumImmunDisTher.2015014188

Source DB:  PubMed          Journal:  For Immunopathol Dis Therap        ISSN: 2151-8017


  71 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

4.  PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.

Authors:  Erin E West; Hyun-Tak Jin; Ata-Ur Rasheed; Pablo Penaloza-Macmaster; Sang-Jun Ha; Wendy G Tan; Ben Youngblood; Gordon J Freeman; Kendall A Smith; Rafi Ahmed
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

5.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 6.  Diversity in T cell memory: an embarrassment of riches.

Authors:  Stephen C Jameson; David Masopust
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.

Authors:  R Omori; J Eguchi; K Hiroishi; S Ishii; A Hiraide; M Sakaki; H Doi; A Kajiwara; T Ito; M Kogo; M Imawari
Journal:  Cancer Gene Ther       Date:  2012-07-13       Impact factor: 5.987

9.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  31 in total

1.  Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression.

Authors:  Matthew Li; Ling-Yee Chin; Sykuri Shukor; Alfred G Tamayo; Marcela V Maus; Biju Parekkadan
Journal:  Autoimmunity       Date:  2019-06-25       Impact factor: 2.815

Review 2.  Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors:  Polina Shindiapina; Lapo Alinari
Journal:  Ther Adv Hematol       Date:  2018-03-05

Review 3.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

4.  Proliferation-competent Tcf1+ CD8 T cells in dysfunctional populations are CD4 T cell help independent.

Authors:  Kristiyan Kanev; Ming Wu; Antar Drews; Patrick Roelli; Christine Wurmser; Madlaina von Hösslin; Dietmar Zehn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-17       Impact factor: 11.205

5.  Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment.

Authors:  Xingzhe Ma; Enguang Bi; Yong Lu; Pan Su; Chunjian Huang; Lintao Liu; Qiang Wang; Maojie Yang; Matthew F Kalady; Jianfei Qian; Aijun Zhang; Anisha A Gupte; Dale J Hamilton; Chengyun Zheng; Qing Yi
Journal:  Cell Metab       Date:  2019-04-25       Impact factor: 27.287

6.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Authors:  Vivek Verma; Rajeev K Shrimali; Shamim Ahmad; Winjie Dai; Hua Wang; Sumin Lu; Rahul Nandre; Pankaj Gaur; Jose Lopez; Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Scott A Hammond; Ming Tan; Jingjing Qi; Phillip Wong; Taha Merghoub; Jedd Wolchok; Nir Hacohen; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

Review 7.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

8.  Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.

Authors:  Mohammad Rashidian; Martin W LaFleur; Vincent L Verschoor; Anushka Dongre; Yun Zhang; Thao H Nguyen; Stephen Kolifrath; Amir R Aref; Christie J Lau; Cloud P Paweletz; Xia Bu; Gordon J Freeman; M Inmaculada Barrasa; Robert A Weinberg; Arlene H Sharpe; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

9.  Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer.

Authors:  Liliang Xia; Hui Wang; Mingjiao Sun; Yi Yang; Chengcheng Yao; Sheng He; Huangqi Duan; Weimin Xia; Ruiming Sun; Yaxian Yao; Zhiwei Chen; Qiong Zhao; Hong Li; Shun Lu; Ying Wang
Journal:  Sci China Life Sci       Date:  2021-01-29       Impact factor: 6.038

10.  Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy.

Authors:  Sonia Iyer; Shuang Zhang; Simge Yucel; Heiko Horn; Sean G Smith; Ferenc Reinhardt; Esmee Hoefsmit; Bimarzhan Assatova; Julia Casado; Marie-Charlotte Meinsohn; M Inmaculada Barrasa; George W Bell; Fernando Pérez-Villatoro; Kaisa Huhtinen; Johanna Hynninen; Jaana Oikkonen; Pamoda M Galhenage; Shailja Pathania; Paula T Hammond; Benjamin G Neel; Anniina Farkkila; David Pépin; Robert A Weinberg
Journal:  Cancer Discov       Date:  2020-11-06       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.